

DAFTAR PUSTAKA

- Arthur CF, Andrej L, Makiko H, Ryan DM, Richard GA, David AF.(2012). *Early detection of ovarian cancer with conventional and contrast-enhanced transvaginal sonography: recent advances and potential improvements.* J Oncol
- American Cancer Society. (2015). *Cancer facts and figures 2015.* <http://www.cancer.org/acs/cid/003130-pdf>. Diakses Maret 2016
- Arania. (2015). Karakteristik pasien kanker ovarium di RS DR. Abdul Moeloek Bandar Lampung tahun 2009-2013. Lapung. Universitas Lampung. Thesis
- Beral, V. (2008). Ovarian Cancer and Oral Contraceptives: Collaborative Reanalysis of Data from 45 Epidemiological Studies Including 23,257 Women with Ovarian Cancer and 87,303 Controls. *Cancer Medical Journal.* 371 (9609), 303-314
- Brech K, Weigert A, Hu J, Popp R, Fisslthaler B, Korff T, Fleming I, geisslinger G, Brune B.(2011).*Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2.* FASEB J;25(2):2408-17
- Budiana ING.(2013). Tumor ovarium : prediksi keganasan prabedah. Medicina.44.p:179-85
- Busmar Boy.(2006). Kanker Ovarium. Dalam: Aziz M. Farid, Andrijono, Saifuddin Abdul Bari. Buku Acuan Nasional Onkologi Ginekologi. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo,pp: 468-524
- Cambruzzi E, Rosane DL, Simone LT, Karla L.(2014).*Relationship between serum levels of CA 125 and the degree of differentiation in ovarian neoplasm.* J Bras Paol Med Lab; 50(1):20-5
- Chen,Vivien W, Ruiz Bernardo, Killeen Jeffrey L, Cote Timothy R, Wu Xiao Cheng, Correa Catherine N. (2003). *Pathology and classification of ovarian tumors*
- Cooper BC, Sood AK, davis CS, Berliare M, Brady MF. (2002). *Preoperative CA 125 levels : an independent prognostic factors for epithelial ovarian cancer.* Obstet Gynecol;100:59-64
- Desen.W.(2008).Buku ajar onkologi klinis. Edisi ke 2. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia,pp 517-26
- Erfan E.Lurui P. Janice MB. Dale BH.(2012). Age dependent increase in prostaglandin pathway coincides with onset of ovarian cancer in laying hens. AACR;87(6): 177-84
- Fachlevy AF, Zulkifli A, Syamsiar SR. (2011). Faktor risiko kanker ovarium di RS wahidin Sudirohusodo.Makassar.Universitas Hasanuddin.Thesis

- Fleming GF, Ronnett BM, Seidman J. (2009). *Epithelial ovarian cancer*. In: Barakat RR, Markman M and Randall ME, eds. Principles and Practice of Gynecologic Oncology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins;763–836
- Foundation of Women's Cancer. (2011). Gynecology Cancer. <http://foundationforwomenscancer.org> – Diakses Februari 2016
- Fures R, Buković D, Hodek B, Klarić B, Herman R, Grubisić G. (2007). Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage. *Coll Antropol*; 109(2):221-7
- Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al.(2007). *Development of ovarian cancer symptom index: possibilities for earlier detection*. *Cancer*; 109(2):221-7
- Hopkins.J. (2008). *What is ovarian cancer*. <http://www.ovariancancer.jhmi.edu/ca125qa.cfm> John Hopkins Pathology - Diakses Februari 2016
- Insin P, Nisa P. (2013). *Evaluation of four risk of malignancy index (RMI) in the preoperative diagnosis of ovarian malignancy at rajavithi hospital*. *Journal of Obstetrics and Gynecology*;21: 163-75
- Junianto.B. (1999). Kanker ovarium di bagian patologi anatomi fakultas kedokteran universitas andalas. Padang. Universitas Andalas. Skripsi
- Junqueira,LC. (2007). Histologi dasar teks dan atlas. Edisi ke 10. Jakarta: EGC,pp 434-41
- Karlina.R. (2006). Kanker ovarium di bagian patologi anatomi fakultas kedokteran universitas andalas. Padang. Universitas Andalas. Skripsi
- Koshiyama,Masafumi. Matsumura,Noriomi. Konishi,Ikuo. (2014). *Recent concepts of ovarian carcinogenesis: type I and type II*. 2014: 1-11
- Kumar V, Abbas Abdul K, Fauslo N, Aster Jon C. (2010). Pathology basis of disease. Edisi ke 8. Philadelphia: Sanders Elsevier,p1047
- Kurman, J.Robert, Sih. le-Ming. (2010). *The origin and pathogenesis of epithelial ovarian cancer*. 34(3): 433-43
- Lukanova A, Kaaks RE.(2005). *Endogenous hormone and ovarian cancer: Epidemiology and current hypothesis*. *Cancer Epidemiol Biomarkers Prev*;14(1): 98-100
- Marpaung (2007). Ketepatan human kalikren 6 sebagai prediksi keganasan ovarium disbanding CA 125. Medan. Universitas Sumatera Utara. Thesis
- Mettler L, Patvelar M, Soyinka AS, Schumutzler A. (2008). *Value of malignancy exclusion of ovarian cyst to laparoscopy*. *J Reproduction med* 5(2): 93-100

- Morch LS, Lokkegaard E, Andreasen AH, et al. (2009). *Hormone therapy and ovarian cancer*. JAMA; 302: 298-305
- Moss E.L, Hollingworth J, Reynolds T.M. (2005). The role of CA 125 in clinical practice, 56(3):306-12
- Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP, Saed GM.(2002).*Effects of prostaglandin E2 on proliferation and apoptosis of epithelial ovarian cancer cells*. J Soc Gynecol Invest; 9:168-73
- Mutch.GD, Jaime P. (2014). *2014 FIGO staging for ovarian, fallopian tube, and peritoneal cancer*, *Gynecologic Oncology*, pp: 401-4
- Nurlailiyani. (2013). Hubungan antara usia pasien dengan derajat keganasan tumor ovarium di RSUD DR. Moewardi tahun 2011-2012. Surakarta. Universitas Sebelas Maret. Skripsi
- Partha MD, Robert CD. (2008). *Early detection of ovarian cancer*. Biomark Med; 2(3): 291–303
- Pemaron.(2013). Modifikasi indeks risiko keganasan sebagai modalitas preoperative untuk memprediksi keganasan tumor ovarium. Denpasar. Universitas Udayana. Thesis
- Yip P et al. (2011). *Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers*. PlosOne
- Rambe, IR. (2013). Profil tumor ganas ovarium di Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Andalas januari 2011- desember 2012. Padang. Universitas Andalas. Skripsi
- Rawung,Max. (2004). Sensitifitas dan spesifisitas petanda tumor CA 125 sebagai prediksi keganasan ovarium. Universitas Sam Ratulangi. Thesis
- Riskesdas. (2013). Infodatin kanker.
http://www.depkes.go.id/resources/download/pusdatin_infodatin-kanker.pdf. Diakses Maret 2016
- Ryerson AB, Eheman C, Burton J, McCall N, Blackman D, Subramanian S, et al. (2007). *Symptoms, diagnose, and time to key diagnostic procedures among older US women with ovarian cancer*. Obstetric Gynecologic. Edisi ke 5,pp1053-61
- Schorge John O (2008). Epithelial Ovarian Cancer. Dalam: Hoffman Barbara L , Schorge John O. Schaffer Joseph I, Halvorson Lisa M, Bradshaw Karen D, Cunningham F. Gary (ed.II). Williams Gynecology. China: The McGraw-Hill Companies, Inc,pp: 853-78.
- Schorge John O. (2008). Ovarian Germ Cell and Sex Cord-Stromal Tumors. Dalam: Hoffman Barbara L, Schorge John O, Schaffer Joseph I, Halvorson

- Lisa M, Bradshaw Karen D, Cunningham F. Gary (ed.II) Williams Gynecology. China: The McGraw-Hill Companies, Inc, pp: 879-97.
- Scholler N, Urban Nicole. (2007). Ca 125 in ovarian cancer, 1(4):513-23
- Scully RE. (1999). *Pathology of ovarian cancer precursor*. J Cell Biochem Suppl; 23: 208-18
- Snell, Richard S. (2006). Anatomi klinik untuk mahasiswa kedokteran; alih bahasa Liliana Sugiharto; Edisi ke 6. Jakarta: EGC
- Speroff, L., Fritz, M.A. (2010). *Clinical Gynecologic and Infertility*, 8th ed, Lippincott William&Wilkins, New York.
- Stanley J. Swierzowski. (2015). *Ovarian cancer risk factors*. Diakses dari <http://www.healthcommunities.com/ovarian-cancer/risk-factors.shtml> pada tanggal 1 Juli 2016
- Tidy, Colin. (2013). Ovarian cancer. Diakses dari <http://www.patient.co.uk/doctor/ovarian-cancer-pro> pada tanggal 17 Oktober 2016.
- Suryantara. (2011). Perbandingan RMI 4 dan 3 sebagai uji diagnostic keganasan tumor ovarium. Thesis
- Uma S, Nisha E. (2006). *Evaluation of new scoring system to differentiate between benign and malignant adnexal mass*. Tae Jurnal of Obstetrics and Gynaecology of India. 56(2)
- Whiteman DC, et al. (2003). *Timing of pregnancy and the risk of epithelial ovarian cancer*. Cancer Epidemiol Biomarker; 12(1): 42-6
- Wei S, Hui L, Bei Z. (2016). The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomedical Reports: 41-4
- Weidner.N, Dabbs J.D, Peterson.M. (2009). Modern surgical pathology. Edisi ke II. Philadelphia. pp: 1356-91
- Winata. (2014). Peran klinis CA 125 pada kanker ovarium. Denpasar. Universitas Udayana. Skripsi
- Yenen MC, et al. (2012). *Comparison between RMI 1-4 in borderline tumor*. Eur.J.Gynaecology Oncology. 33(2). p: 168-73
- Zarchi MK, Mojaver SP, Rouhi M, Hossein S, Hekmatimognaddam, Mognadham RN, Anari PY, Teimori S. (2015). *Diagnostic value of the Risk of Malignancy Index for detection of pelvic malignancies compared with pathology*. Oman med. 30(6). p: 409-17